Sr89
Sr-89 (strontium-89) is a radioactive isotope of strontium used as a radiopharmaceutical for palliation of bone pain associated with skeletal metastases. It decays by beta emission to stable yttrium-89 with a half-life of 50.5 days.
In the body, strontium behaves chemically like calcium and accumulates in bone, particularly in areas of high
Administration: It is given by intravenous injection as strontium-89 chloride (brand Metastron in some jurisdictions). A
Safety and monitoring: The principal toxicity is bone marrow suppression, which can lead to reduced blood cell
Efficacy and limitations: Sr-89 provides palliation for metastatic bone pain but does not treat the underlying